Skip to main content
NCBI home page
The American Journal of Pathology logoLink to The American Journal of Pathology
. 1992 Apr;140(4):897–906.

Activation of the contact system in lethal hypotensive bacteremia in a baboon model.

R A Pixley 1, R A DeLa Cadena 1, J D Page 1, N Kaufman 1, E G Wyshock 1, R W Colman 1, A Chang 1, F B Taylor Jr 1
PMCID: PMC1886362  PMID: 1373271

Abstract

The hypotension in septicemia is believed to be mediated by the combined action of many mediators including cytokines, prostaglandins, and complement components. To evaluate the contribution of the contact/kinin-forming system to hypotension, the authors used an established experimental baboon model of bacteremia in which two concentrations of Escherichia Coli (E. coli) were used to produce lethal and nonlethal hypotension. The lethal group (n = 5) developed irreversible hypotension that significantly correlated with the decline in levels of high molecular weight kininogen (HK) and an increase in alpha 2 macroglobulin-kallikrein complexes (alpha 2M-kal). The nonlethal group (n = 9) experienced reversible hypotension, a less striking decline in HK, and only slight elevation in alpha 2M-kal. No significant changes were found in levels of factor XII, prekallikrein, and factor XI in either group. A significant change in the contact system, which reflects the fatal outcome, is the rise in alpha 2M-kal. This study suggests that irreversible hypotension correlates with prolonged activation of the contact system.

Full text

PDF
897

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abbink J. J., Nuijens J. H., Eerenberg A. J., Huijbregts C. C., Strack van Schijndel R. J., Thijs L. G., Hack C. E. Quantification of functional and inactivated alpha 2-macroglobulin in sepsis. Thromb Haemost. 1991 Jan 23;65(1):32–39. [PubMed] [Google Scholar]
  2. Beutler B., Cerami A. Cachectin: more than a tumor necrosis factor. N Engl J Med. 1987 Feb 12;316(7):379–385. doi: 10.1056/NEJM198702123160705. [DOI] [PubMed] [Google Scholar]
  3. Carmona R. H., Tsao T. C., Trunkey D. D. The role of prostacyclin and thromboxane in sepsis and septic shock. Arch Surg. 1984 Feb;119(2):189–192. doi: 10.1001/archsurg.1984.01390140053009. [DOI] [PubMed] [Google Scholar]
  4. Colman R. W. The role of plasma proteases in septic shock. N Engl J Med. 1989 May 4;320(18):1207–1209. doi: 10.1056/NEJM198905043201809. [DOI] [PubMed] [Google Scholar]
  5. Creasey A. A., Stevens P., Kenney J., Allison A. C., Warren K., Catlett R., Hinshaw L., Taylor F. B., Jr Endotoxin and cytokine profile in plasma of baboons challenged with lethal and sublethal Escherichia coli. Circ Shock. 1991 Feb;33(2):84–91. [PubMed] [Google Scholar]
  6. Cugno M., Nuijens J., Hack E., Eerenberg A., Frangi D., Agostoni A., Cicardi M. Plasma levels of C1- inhibitor complexes and cleaved C1- inhibitor in patients with hereditary angioneurotic edema. J Clin Invest. 1990 Apr;85(4):1215–1220. doi: 10.1172/JCI114555. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. De La Cadena R. A., Scott C. F., Colman R. W. Evaluation of a microassay for human plasma prekallikrein. J Lab Clin Med. 1987 May;109(5):601–607. [PubMed] [Google Scholar]
  8. Fisher C. A., Schmaier A. H., Addonizio V. P., Colman R. W. Assay of prekallikrein in human plasma: comparison of amidolytic, esterolytic, coagulation, and immunochemical assays. Blood. 1982 May;59(5):963–970. [PubMed] [Google Scholar]
  9. Ghebrehiwet B., Silverberg M., Kaplan A. P. Activation of the classical pathway of complement by Hageman factor fragment. J Exp Med. 1981 Mar 1;153(3):665–676. doi: 10.1084/jem.153.3.665. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Gonias S. L., Pizzo S. V. Chemical and structural modifications of alpha 2-macroglobulin: effects on receptor binding and endocytosis studied in an in vivo model. Ann N Y Acad Sci. 1983;421:457–471. doi: 10.1111/j.1749-6632.1983.tb18139.x. [DOI] [PubMed] [Google Scholar]
  11. Hack C. E., Nuijens J. H., Felt-Bersma R. J., Schreuder W. O., Eerenberg-Belmer A. J., Paardekooper J., Bronsveld W., Thijs L. G. Elevated plasma levels of the anaphylatoxins C3a and C4a are associated with a fatal outcome in sepsis. Am J Med. 1989 Jan;86(1):20–26. doi: 10.1016/0002-9343(89)90224-6. [DOI] [PubMed] [Google Scholar]
  12. Harpel P. C., Lewin M. F., Kaplan A. P. Distribution of plasma kallikrein between C-1 inactivator and alpha 2-macroglobulin in plasma utilizing a new assay for alpha 2-macroglobulin-kallikrein complexes. J Biol Chem. 1985 Apr 10;260(7):4257–4263. [PubMed] [Google Scholar]
  13. Hauert J., Nicoloso G., Schleuning W. D., Bachmann F., Schapira M. Plasminogen activators in dextran sulfate-activated euglobulin fractions: a molecular analysis of factor XII- and prekallikrein-dependent fibrinolysis. Blood. 1989 Mar;73(4):994–999. [PubMed] [Google Scholar]
  14. Herman C. M., Oshima G., Erdös E. G. The effect of adrenocorticosteroid pretreatment on kinin system and coagulation response to septic shock in the baboon. J Lab Clin Med. 1974 Nov;84(5):731–739. [PubMed] [Google Scholar]
  15. Hinshaw L. B., Brackett D. J., Archer L. T., Beller B. K., Wilson M. F. Detection of the 'hyperdynamic state' of sepsis in the baboon during lethal E. coli infusion. J Trauma. 1983 May;23(5):361–365. doi: 10.1097/00005373-198305000-00001. [DOI] [PubMed] [Google Scholar]
  16. Hirsch E. F., Nakajima T., Oshima G., Erdös E. G., Herman C. M. Kinin system responses in sepsis after trauma in man. J Surg Res. 1974 Sep;17(3):147–153. doi: 10.1016/0022-4804(74)90101-2. [DOI] [PubMed] [Google Scholar]
  17. Kalter E. S., Daha M. R., ten Cate J. W., Verhoef J., Bouma B. N. Activation and inhibition of Hageman factor-dependent pathways and the complement system in uncomplicated bacteremia or bacterial shock. J Infect Dis. 1985 Jun;151(6):1019–1027. doi: 10.1093/infdis/151.6.1019. [DOI] [PubMed] [Google Scholar]
  18. Kalter E. S., van Dijk W. C., Timmerman A., Verhoef J., Bouma B. N. Activation of purified human plasma prekallikrein triggered by cell wall fractions of Escherichia coli and Staphylococcus aureus. J Infect Dis. 1983 Oct;148(4):682–691. doi: 10.1093/infdis/148.4.682. [DOI] [PubMed] [Google Scholar]
  19. Kaufman N., Page J. D., Pixley R. A., Schein R., Schmaier A. H., Colman R. W. Alpha 2-macroglobulin-kallikrein complexes detect contact system activation in hereditary angioedema and human sepsis. Blood. 1991 Jun 15;77(12):2660–2667. [PubMed] [Google Scholar]
  20. Kellermeyer R. W., Graham R. C., Jr Kinins--possible physiologic and pathologic roles in man. N Engl J Med. 1968 Oct 3;279(14):754–759. doi: 10.1056/NEJM196810032791406. [DOI] [PubMed] [Google Scholar]
  21. Kleniewski J., Donaldson V. H. Comparison of human high molecular weight kininogen digestion by plasma kallikrein and by plasmin. A revised method of purification of high molecular weight kininogen. J Lab Clin Med. 1987 Apr;109(4):469–479. [PubMed] [Google Scholar]
  22. Kleniewski J., Donaldson V. Granulocyte elastase cleaves human high molecular weight kininogen and destroys its clot-promoting activity. J Exp Med. 1988 Jun 1;167(6):1895–1907. doi: 10.1084/jem.167.6.1895. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. MASON D. T., MELMON K. L. EFFECTS OF BRADYKININ ON FOREARM VENOUS TONE AND VASCULAR RESISTANCE IN MAN. Circ Res. 1965 Aug;17:106–113. doi: 10.1161/01.res.17.2.106. [DOI] [PubMed] [Google Scholar]
  24. MacLean L. D., Mulligan W. G., McLean A. P., Duff J. H. Patterns of septic shock in man--a detailed study of 56 patients. Ann Surg. 1967 Oct;166(4):543–562. doi: 10.1097/00000658-196710000-00004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Mason J. W., Kleeberg U., Dolan P., Colman R. W. Plasma kallikrein and Hageman factor in Gram-negative bacteremia. Ann Intern Med. 1970 Oct;73(4):545–551. doi: 10.7326/0003-4819-73-4-545. [DOI] [PubMed] [Google Scholar]
  26. Mason J. W., Kleeberg U., Dolan P., Colman R. W. Plasma kallikrein and Hageman factor in Gram-negative bacteremia. Ann Intern Med. 1970 Oct;73(4):545–551. doi: 10.7326/0003-4819-73-4-545. [DOI] [PubMed] [Google Scholar]
  27. Molla A., Yamamoto T., Akaike T., Miyoshi S., Maeda H. Activation of hageman factor and prekallikrein and generation of kinin by various microbial proteinases. J Biol Chem. 1989 Jun 25;264(18):10589–10594. [PubMed] [Google Scholar]
  28. Morrison D. C., Cochrane C. G. Direct evidence for Hageman factor (factor XII) activation by bacterial lipopolysaccharides (endotoxins). J Exp Med. 1974 Sep 1;140(3):797–811. doi: 10.1084/jem.140.3.797. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Nies A. S., Forsyth R. P., Williams H. E., Melmon K. L. Contribution of kinins to endotoxin shock in unanesthetized Rhesus monkeys. Circ Res. 1968 Feb;22(2):155–164. doi: 10.1161/01.res.22.2.155. [DOI] [PubMed] [Google Scholar]
  30. Nuijens J. H., Eerenberg-Belmer A. J., Huijbregts C. C., Schreuder W. O., Felt-Bersma R. J., Abbink J. J., Thijs L. G., Hack C. E. Proteolytic inactivation of plasma C1- inhibitor in sepsis. J Clin Invest. 1989 Aug;84(2):443–450. doi: 10.1172/JCI114185. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Nuijens J. H., Huijbregts C. C., Eerenberg-Belmer A. J., Abbink J. J., Strack van Schijndel R. J., Felt-Bersma R. J., Thijs L. G., Hack C. E. Quantification of plasma factor XIIa-Cl(-)-inhibitor and kallikrein-Cl(-)-inhibitor complexes in sepsis. Blood. 1988 Dec;72(6):1841–1848. [PubMed] [Google Scholar]
  32. O'Donnell T. F., Jr, Clowes G. H., Jr, Talamo R. C., Colman R. W. Kinin activation in the blood of patients with sepsis. Surg Gynecol Obstet. 1976 Oct;143(4):539–545. [PubMed] [Google Scholar]
  33. PROCTOR R. R., RAPAPORT S. I. The partial thromboplastin time with kaolin. A simple screening test for first stage plasma clotting factor deficiencies. Am J Clin Pathol. 1961 Sep;36:212–219. doi: 10.1093/ajcp/36.3.212. [DOI] [PubMed] [Google Scholar]
  34. Parker M. M., Shelhamer J. H., Natanson C., Alling D. W., Parrillo J. E. Serial cardiovascular variables in survivors and nonsurvivors of human septic shock: heart rate as an early predictor of prognosis. Crit Care Med. 1987 Oct;15(10):923–929. doi: 10.1097/00003246-198710000-00006. [DOI] [PubMed] [Google Scholar]
  35. Pixley R. A., Colman R. W. Purification of human factor XII from plasma using zinc chelate affinity chromatography. Thromb Res. 1986 Jan 1;41(1):89–98. doi: 10.1016/0049-3848(86)90282-3. [DOI] [PubMed] [Google Scholar]
  36. Pixley R. A., Schapira M., Colman R. W. The regulation of human factor XIIa by plasma proteinase inhibitors. J Biol Chem. 1985 Feb 10;260(3):1723–1729. [PubMed] [Google Scholar]
  37. Robinson J. A., Klondnycky M. L., Loeb H. S., Racic M. R., Gunnar R. M. Endotoxin, prekallikrein, complement and systemic vascular resistance. Sequential measurements in man. Am J Med. 1975 Jul;59(1):61–67. doi: 10.1016/0002-9343(75)90322-8. [DOI] [PubMed] [Google Scholar]
  38. Schapira M., Scott C. F., Colman R. W. Contribution of plasma protease inhibitors to the inactivation of kallikrein in plasma. J Clin Invest. 1982 Feb;69(2):462–468. doi: 10.1172/JCI110470. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Schapira M., Silver L. D., Scott C. F., Schmaier A. H., Prograis L. J., Jr, Curd J. G., Colman R. W. Prekallikrein activation and high-molecular-weight kininogen consumption in hereditary angioedema. N Engl J Med. 1983 May 5;308(18):1050–1053. doi: 10.1056/NEJM198305053081802. [DOI] [PubMed] [Google Scholar]
  40. Scott C. F., Colman R. W. A simple and accurate microplate assay for the determination of factor XI in plasma. J Lab Clin Med. 1988 Jun;111(6):708–714. [PubMed] [Google Scholar]
  41. Scott C. F., Silver L. D., Purdon A. D., Colman R. W. Cleavage of human high molecular weight kininogen by factor XIa in vitro. Effect on structure and function. J Biol Chem. 1985 Sep 5;260(19):10856–10863. [PubMed] [Google Scholar]
  42. Scott C. F., Silver L. D., Schapira M., Colman R. W. Cleavage of human high molecular weight kininogen markedly enhances its coagulant activity. Evidence that this molecule exists as a procofactor. J Clin Invest. 1984 Apr;73(4):954–962. doi: 10.1172/JCI111319. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Smith-Erichsen N., Aasen A. O., Gallimore M. J., Amundsen E. Studies of components of the coagulation systems in normal individuals and septic shock patients. Circ Shock. 1982;9(5):491–497. [PubMed] [Google Scholar]
  44. Steranka L. R., Farmer S. G., Burch R. M. Antagonists of B2 bradykinin receptors. FASEB J. 1989 Jul;3(9):2019–2025. doi: 10.1096/fasebj.3.9.2545496. [DOI] [PubMed] [Google Scholar]
  45. Stevens J. H., O'Hanley P., Shapiro J. M., Mihm F. G., Satoh P. S., Collins J. A., Raffin T. A. Effects of anti-C5a antibodies on the adult respiratory distress syndrome in septic primates. J Clin Invest. 1986 Jun;77(6):1812–1816. doi: 10.1172/JCI112506. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Suffredini A. F., Fromm R. E., Parker M. M., Brenner M., Kovacs J. A., Wesley R. A., Parrillo J. E. The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med. 1989 Aug 3;321(5):280–287. doi: 10.1056/NEJM198908033210503. [DOI] [PubMed] [Google Scholar]
  47. Taylor F. B., Jr, Chang A., Esmon C. T., D'Angelo A., Vigano-D'Angelo S., Blick K. E. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest. 1987 Mar;79(3):918–925. doi: 10.1172/JCI112902. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Taylor F. B., Jr, Emerson T. E., Jr, Jordan R., Chang A. K., Blick K. E. Antithrombin-III prevents the lethal effects of Escherichia coli infusion in baboons. Circ Shock. 1988 Nov;26(3):227–235. [PubMed] [Google Scholar]
  49. Wachtfogel Y. T., Kucich U., James H. L., Scott C. F., Schapira M., Zimmerman M., Cohen A. B., Colman R. W. Human plasma kallikrein releases neutrophil elastase during blood coagulation. J Clin Invest. 1983 Nov;72(5):1672–1677. doi: 10.1172/JCI111126. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Wakabayashi G., Gelfand J. A., Burke J. F., Thompson R. C., Dinarello C. A. A specific receptor antagonist for interleukin 1 prevents Escherichia coli-induced shock in rabbits. FASEB J. 1991 Mar 1;5(3):338–343. doi: 10.1096/fasebj.5.3.1825816. [DOI] [PubMed] [Google Scholar]
  51. Wilson D. D., de Garavilla L., Kuhn W., Togo J., Burch R. M., Steranka L. R. D-Arg-[Hyp3-D-Phe7]-bradykinin, a bradykinin antagonist, reduces mortality in a rat model of endotoxic shock. Circ Shock. 1989 Feb;27(2):93–101. [PubMed] [Google Scholar]
  52. Wong P., Colman R. W., Talamo R. C., Babior B. M. Kallikrein-bradykinin system in chronic alcoholic liver disease. Ann Intern Med. 1972 Aug;77(2):205–209. doi: 10.7326/0003-4819-77-2-205. [DOI] [PubMed] [Google Scholar]
  53. Ziccardi R. J. Activation of the early components of the classical complement pathway under physiologic conditions. J Immunol. 1981 May;126(5):1769–1773. [PubMed] [Google Scholar]
  54. Ziegler E. J., Fisher C. J., Jr, Sprung C. L., Straube R. C., Sadoff J. C., Foulke G. E., Wortel C. H., Fink M. P., Dellinger R. P., Teng N. N. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med. 1991 Feb 14;324(7):429–436. doi: 10.1056/NEJM199102143240701. [DOI] [PubMed] [Google Scholar]
  55. van der Graaf F., Koedam J. A., Bouma B. N. Inactivation of kallikrein in human plasma. J Clin Invest. 1983 Jan;71(1):149–158. doi: 10.1172/JCI110743. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from The American Journal of Pathology are provided here courtesy of American Society for Investigative Pathology

RESOURCES